| Cash Flow | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Net income | 3,660,300 | 2,200,300 | 808,700 | 3,494,900 |
| Depreciation and amortization | 398,700 | 262,000 | 126,900 | 356,500 |
| Stock-based compensation expense | 744,400 | 507,400 | 255,700 | 678,400 |
| Gains on marketable and other securities, net | 967,600 | 389,900 | 139,900 | 331,200 |
| Other, net | 1,400 | 17,700 | -3,200 | 31,900 |
| Deferred income taxes | 552,900 | 274,300 | 139,100 | 477,100 |
| Decrease (increase) in accounts receivable | -549,300 | -629,600 | -657,800 | 436,200 |
| Increase in inventories | 277,400 | 194,800 | 152,300 | 502,000 |
| Increase in prepaid expenses and other assets | 458,100 | 410,200 | 179,500 | 352,200 |
| (decrease) increase in deferred revenue | -48,600 | -125,200 | 17,700 | 249,000 |
| Increase in accounts payable, accrued expenses, and other liabilities | 761,500 | 2,300 | -214,100 | 509,500 |
| Total adjustments | 147,900 | -10,800 | 236,400 | -337,200 |
| Net cash provided by operating activities | 3,808,200 | 2,189,500 | 1,045,100 | 3,157,700 |
| Purchases of marketable and other securities | 8,914,600 | 5,394,400 | 2,539,300 | 14,664,500 |
| Sales or maturities of marketable and other securities | 8,991,200 | 5,626,200 | 3,458,300 | 12,445,300 |
| Capital expenditures | 649,700 | 448,300 | 229,300 | 556,300 |
| Payments for intangible assets | 273,300 | 230,000 | 42,200 | 58,300 |
| Proceeds from sale of property, plant, and equipment | 0 | 0 | - | 20,100 |
| Acquisitions, net of cash acquired | 3,000 | 0 | - | 5,000 |
| Net cash used in investing activities | -849,400 | -446,500 | 647,500 | -2,818,700 |
| Proceeds from issuance of common stock | 132,400 | 92,100 | 60,600 | 1,374,400 |
| Payments in connection with common stock tendered for employee tax obligations | 12,900 | 9,900 | 4,300 | 775,700 |
| Repurchases of common stock | 2,766,900 | 2,102,900 | 1,041,400 | 1,630,300 |
| Dividends paid | 277,600 | 186,400 | 93,800 | - |
| Other | -10,300 | -10,300 | -10,300 | -33,400 |
| Net cash used in financing activities | -2,935,300 | -2,217,400 | -1,089,200 | -1,065,000 |
| Effect of exchange rate changes on cash, cash equivalents, and restricted cash | 600 | 1,000 | 600 | 0 |
| Net increase (decrease) in cash, cash equivalents, and restricted cash | 24,100 | -473,400 | 604,000 | -726,000 |
| Cash and cash equivalents at beginning of period | 2,489,000 | 2,489,000 | 2,489,000 | 2,737,800 |
| Cash and cash equivalents at end of period | 2,513,100 | 2,015,600 | 3,093,000 | 2,011,800 |
REGENERON PHARMACEUTICALS, INC. (REGN)
REGENERON PHARMACEUTICALS, INC. (REGN)